AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

While Moderna was viewed as a front-runner in the race for a Covid-19 vaccine, competition is mounting. On Monday, Oxford University, which is developing a Covid-19 vaccine candidate along with AstraZeneca, published some positive data on phase 1/2 trials, indicating that the vaccine was.

Should Oxford-AstraZeneca’s Progress Worry Moderna?

Johnson & Johnson

Novavax

Pfizer

Vaxart

The U.S. government is pouring money into coronavirus vaccine development, and a handful of companies are cashing in.

Everything You Need to Know About Operation Warp Speed's Coronavirus Vaccine Accelerator

BioNTech SE

New research could mean the market opportunity for COVID-19 vaccines might be bigger than expected. Or maybe not.

Could These Findings Dramatically Change the Opportunities for COVID-19 Vaccine Stocks?

Merck

Drug company executives insisted Tuesday they aren’t cutting corners in fast-tracking development of potential vaccines to prevent infection of the coronavirus.

Pharma executives promise Congress they aren't cutting corners in fast tracking coronavirus vaccine

There's more good news in the race to develop a COVID-19 vaccine.

3 Key Things You'll Want to Know About AstraZeneca's COVID-19 Vaccine Results

The viral-vector based vaccine that AstraZeneca licensed from Oxford takes the lead.

AstraZeneca's Coronavirus Vaccine Candidate Posts Positive Results

Market participants still aren't sure what to expect as earnings season continues.

Markets Open Mixed Monday Morning; AstraZeneca Reveals COVID-19 Vaccine Data While Moderna Gets Downgraded

Shares of AstraZeneca AZN, -3.91% AZN, +1.44% were down 3.4% in trading on Monday after a medical journal published a study that found the company's COVID-19 vaccine candidate produced antibody and T-cell responses in participants in a Phase 1/2 clinical trial.

AstraZeneca's stock falls 3% as results from early-stage study on coronavirus vaccine are published

Oxford University and AstraZeneca plc (NYSE: AZN) released an interim readout Monday from the Phase 1/2 study of their candidate coronavirus vaccine candidate AZD1222, previously known as ChAdOx1 nCoV-19.

AstraZeneca Joins Other Coronavirus Vaccine Frontrunners In Reporting Positive Efficacy, Safety Data

The vaccine is still in early-stage clinical trials, and it is yet to be seen whether it can protect people against the virus.

Promising Sign As Coronavirus Vaccine Developed By AstraZeneca And Oxford University Appears Safe, Early Trials Show

Shares of AstraZeneca AZN, -3.09% AZN, 1.14% were down 3.4% in trading on Monday after a medical journal published a study that found the company's COVID-19 vaccine candidate produced antibody and T-cell responses in participants in a Phase 1/2 clinical trial.

AstraZeneca's stock fall 3% as results from early-stage study on coronavirus vaccine are published

A potential coronavirus vaccine developed by Oxford University in the U.K. has produced an immune response in an early-stage human trial, according to newly released data published Monday in medical journal The Lancet.

Oxford University's coronavirus vaccine shows positive immune response in an early trial

Shares of AstraZeneca AZN, +6.39% were active in premarket trading on Monday as investors prepare for the release of Phase 1 clinical trial data for the COVID-19 vaccine candidate being developed by the drugmaker and the U.K.

AstraZeneca's shares are up 0.1% as investors prepare for vaccine data

GlaxoSmithKline

Inovio Pharmaceuticals

Sinovac Biotech

Leaders and laggards in the COVID-19 vaccine race -- and how likely they are to win approval.

Here Are All the COVID-19 Vaccines Currently in Clinical Testing

This company’s shares will climb if it wins the coronavirus vaccine race. If it doesn’t, gains still may be on the horizon.

The 1 Coronavirus Stock I’d Buy Right Now

A coronavirus vaccine has the potential to not only save countless lives, but also to mitigate trillions in economic damage.

Which Biotech Company Has the Most Promising Coronavirus Vaccine?

Gilead Sciences

The markets are ready for a steady flow of updates from COVID-19 drug and vaccine developers as the world races to contain the pandemic and bring back some semblance of normalcy.

BofA On 3 Coronavirus Vaccine Frontrunners, The Remdesivir Opportunity And Antibodies

AstraZeneca's (AZN) Farxiga gets Fast Track status to reduce the risk of cardiovascular death or hospitalization for heart failure following a heart attack in adult patients.

AstraZeneca's Farxiga Gets Fast Track Tag for New Indication

Regeneron Pharmaceuticals

Dozens are racing to develop a vaccine that could end the COVID-19 pandemic; so far, these companies look most likely to succeed.

4 Coronavirus Stocks to Watch This Summer

AstraZeneca continues to be one of my favorite dividend and growth stocks.

A Crucial COVID-19 Vaccine Update Is Coming From AstraZeneca On Monday

Bristol-Myers

Sanofi

In a previous article published in GuruFocus, I looked at the top five pharma companies on EvaluatePharma’s list ranked by sales the firms are expected to achieve in 2026.

Pharma Companies Look to Blockbusters to Drive Sales

AstraZeneca (AZN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

AstraZeneca (AZN) Looks Good: Stock Adds 7.5% in Session

American Airlines

Beyond Meat

Unilever

Moderna, UnitedHeath, Beyond Meat, American Airlines and AstraZeneca were our top stock trades from Wednesday -- and here's why.

5 Top Stock Trades for Thursday: MRNA, AZN, AAL, BYND, UNH

AstraZeneca plc (NYSE: AZN) shares are trading higher on Wednesday after the company announced its collaboration with IQVIA to accelerate the development of a potential new vaccine for COVID-19.

Why AstraZeneca's Stock Is Trading Higher Today

AstraZeneca will soon publish positive data for its University of Oxford-partnered coronavirus vaccine, according to a report that sent AZN stock higher Wednesday.
The post AstraZeneca Pops On Bullish Expectations For Coronavirus Vaccine Data appeared first on Investor's Business Daily.

News for AstraZeneca Stock (AZN)